Millennium Management’s BridgeBio Pharma BBIO Stock Holding History

Millennium Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$2.6M	–	6012
2025 Q3	$2.6M	Buy	50,000 +26,300	+111%	+$1.28M	﹤0.01%	3806
2025 Q2	$1.02M	Buy	23,700 +10,000	+73%	+$364K	﹤0.01%	4387
2025 Q1	$474K	Buy	+13,700	New	+$462K	﹤0.01%	4849
2024 Q2	–	Sell	-15,700	Closed	-$485K	–	5879
2024 Q1	$485K	Buy	+15,700	New	+$534K	﹤0.01%	4841
2023 Q3	–	Sell	-302,700	Closed	-$5.21M	–	6117
2023 Q2	$5.21M	Buy	302,700 +199,900	+194%	+$3.01M	﹤0.01%	2641
2023 Q1	$1.7M	Buy	+102,800	New	+$1.2M	﹤0.01%	3591
2022 Q2	–	Sell	-100,000	Closed	-$1.01M	–	6966
2022 Q1	$1.01M	Buy	100,000 +40,000	+67%	+$411K	﹤0.01%	4499
2021 Q4	$1M	Buy	+60,000	New	+$2.54M	﹤0.01%	4406
2021 Q1	–	Sell	-8,000	Closed	-$569K	–	5903
2020 Q4	$569K	Buy	+8,000	New	+$386K	﹤0.01%	4095

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's BBIO Position: Q1 2026 in Review

Millennium Management increased its BridgeBio Pharma (BBIO) stake by 1,631% in Q1 2026, buying an estimated $43.3M and bringing the position to 633,283 shares worth $47M. The position accounts for 0.02% of the portfolio, ranked #863.

Millennium Management first reported a position in BBIO in Q2 2019 and has held it in 25 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Millennium Management held 633,283 shares of BridgeBio Pharma worth $47M as of Q1 2026.
Millennium Management bought 596,698 BridgeBio Pharma shares in Q1 2026, an estimated $43.3M.
BridgeBio Pharma made up 0.02% of Millennium Management's portfolio in Q1 2026, its #863 holding.
Millennium Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 25 quarters since.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.